Overview

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.
Phase:
Phase 3
Details
Lead Sponsor:
University of South Florida
Collaborator:
Bristol-Myers Squibb
Treatments:
Apixaban
Warfarin